Today, ACI, along with 75 organizations and activists, sent a letter to Congress opposing Medicare-for-All legislation that includes provisions for the government to set prescription prices. The letter is available online.
Today, ACI joined 70 other organizations in opposition to the prescription drug pricing bill offered by House Speaker Nancy Pelosi. The bill would impose excise taxes up to 95% on hundreds of prescription medicines. You can read the coalition letter online. 10-15-19 Coalition Letter Opposed to Pelosi Drug Tax Plan
It’s tempting to think that legalizing drug importation would immediately give U.S. consumers access to medicines at the prices available in other developed countries. In reality, however, the Safe Importation Action Plan would expose American consumers to significant health risks while achieving meager cost reductions, if any at all. Visit Real Clear Health to lean […]
In partnership with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) has recently proposed that certain pharmaceuticals should be cleared for import from Canada. Although the proposal seeks to lower prices for consumers, it poses critical unintended risks to both American businesses and patients. To read why, visit Townhall.
In an effort to reverse the continuing rise of prescription drug prices, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) are mulling the idea of allowing drug imports from Canada. Their so-called “Safe Importation Action Plan,” however, is a misnomer—the policy could expose countless Americans to potentially deadly […]
Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]
Today, ACI released a coalition letter to Congress in opposition to creating an inflationary rebate penalty in Medicare Part D. You can download and print the letter here.
Americans are right to be concerned about the high out-of-pocket costs of pharmaceuticals. But targeting America’s free enterprise system is the wrong solution. Putting bureaucrats abroad in charge of deciding how our drug market operates may save some money now, but it’ll hurt consumers in the long-run. This op-ed, published in Real Clear Health, explains […]
When one thinks of counterfeit goods, it can conjure up images of customers being duped into buying inferior quality designer bags or other fashion knockoffs. However, when it comes to the manufacturing, distribution and sale of counterfeit medications, the outcomes can be much more serious and life threatening. Most consumers probably don’t realize that counterfeit […]
Washington, D.C. — Today, The American Consumer Institute Center for Citizen Research (ACI), a non-profit consumer education and research organization, released a white paper, “How International Reference Pricing for Prescription Drugs Would Hurt American Consumers.” Recently, some lawmakers and other federal officials have promoted international reference pricing as a way to reduce drug costs for […]